Enfermedad Respiratoria Exacerbada por Aspirina. Situación actual y casos clínicos.

Karen Estefanía Hernández-Moreno, Ricardo Cardona-Villa

Resumen


La enfermedad respiratoria exacerbada por aspirina (EREA) comprende un conjunto de signos y síntomas que involucran principalmente la vía aérea superior e inferior tras el consumo de inhibidores de la enzima ciclooxigenasa (COX). Las  reacciones adversas que se presentan no se consideran una alergia y son comunes a todos los antiinflamatorios no esteroideos (AINEs), por lo que la reactividad cruzada entre estos es lo común. Es importante un adecuado diagnóstico y educación en el uso o eliminación de los diferentes AINEs, al igual que una alternativa analgésica, comprobada mediante pruebas de provocación. Su manejo incluye procedimientos quirúrgicos para el control de los pólipos nasales, tratamiento farmacológico para el control del asma y desensibilización con aspirina en individuos seleccionados. En esta revisión presentamos una serie de casos clínicos, al igual que repasaremos aspectos claves de la enfermedad como la epidemiologia, fisiopatología, manifestaciones clínicas, diagnóstico y manejo.


Palabras clave


reacción de hipersensibilidad, enzima ciclooxigenasa, antinflamatorio no esteroideo, rinosinusitis crónica, asma, pólipos nasales, desensibilización a la aspirina.

Referencias


Sakalar EG, Muluk NB, Kar M, Cingi C. Aspirin-exacerbated respiratory disease and current treatment modalities. Eur Arch Otorhinolaryngol. 2017;274(3):1292-1300. doi:10.1007/s00405-016-4273-1.

Laidlaw TM, Boyce JA. Clinical Implications of Basic Research Aspirin-Exacerbated Respiratory Disease — New Prime Suspects. N Engl J Med. 2016;374(5):484-488.

Steinke JW, Ph D, Negri J, Liu L, Payne SC, Borish L. Aspirin Activation of Eosinophils and Mast Cells: Implications in the Pathogenesis of Aspirin-Exacerbated Respiratory Disease. J Immunol. 2015;193(1):41-47. doi:10.4049/jimmunol.1301753.Aspirin.

Stevenson DD, Szczeklik A, Jolla L. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006;118(4):773-786. doi:10.1016/j.jaci.2006.07.024.

Samter M, Beers R. Intolerance to Aspirin Clinical Studies and Consideration of its Pathogenesis. Ann Intern Med. 1968;68(5):975-983.

Cahill KN, Boyce JA. Aspirin-exacerbated respiratory disease: Mediators and mechanisms of a clinical disease. J Allergy Clin Immunol. 2016;139(3):764-766. doi:10.1016/j.jaci.2016.09.025.

Mullol J, Picado C. Rhinosinusitis and Nasal Polyps in Aspirin-Exacerbated Respiratory Disease. Immunol Allergy Clin NA. 2017;33(2):163-176. doi:10.1016/j.iac.2012.11.002.

Macy E, Bernstein JA, Castells MC, et al. Aspirin challenge and desensitization for aspirin- exacerbated respiratory disease : a practice paper. Ann Allergy Asthma Immunol. 2007;98(2):172-174. doi:10.1016/S1081-1206(10)60692-8.

Laidlaw TM, Cahill KN. Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs. J Allergy Clin Immunol Pract. 2017;5(3):537-545. doi:10.1016/j.jaip.2016.10.021.

Jares EJ, Sánchez-Borges M, Cardona-Villa R, et al. Multinational experience with hypersensitivity drug reactions in Latin America. Ann Allergy, Asthma Immunol. 2014;113(3):282-289. doi:10.1016/j.anai.2014.06.019.

Rajan JP, Wineinger NE, Stevenson DD, White AA, Diego S. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients : A meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676-681.e1. doi:10.1016/j.jaci.2014.08.020.

Stevens WW, Peters AT, Hirsch AG, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2017;5(4):1061-1070. doi:10.1016/j.jaip.2016.12.027.

Vento SI, Ertama LO, Hyto ML, et al. Nasal polyposis : clinical course during 20 years. Ann Allergy Asthma Immunol. 2000;85(3):209-214. doi:10.1016/S1081-1206(10)62468-4.

Settipane GA, Chafee FH. Nasal polyps A review in asthma and rhinitis of 6,037 patients. J Allergy Clin Immunol. 1977;59(1):17-21.

Cahill KN, Laidlaw TM. Pathogenesis of Aspirin-Induced Reactions in Aspirin-Exacerbated Respiratory Disease. Immunol Allergy Clin North Am. 2016;36(4):681-691. doi:10.1016/j.iac.2016.06.005.

Parker AR, Ayars AG, Altman MC, Henderson WR. Lipid Mediators in Aspirin-Exacerbated Respiratory Disease. Immunol Allergy Clin North Am. 2016;36(4):749-763. doi:10.1016/j.iac.2016.06.009.

Christie PE, Tagari P, Ford-hutchinson AW, et al. Urinary Leukotriene E 4 Concentrations Increase after Aspirin Challenge in Aspirin-sensitive Asthmatic Subjects 1- 3. Am Rev Respir Dis. 1990;143(5 Pt 1):1025-1029.

Hill J, Burnett T, Katial R. Mechanisms of Benefit with Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease. Immunol Allergy Clin North Am. 2016;36(4):735-747. doi:10.1016/j.iac.2016.06.011.

Cowburn AS, Sladek K, Soja J, et al. Overexpression of Leukotriene C 4 Synthase in Bronchial Biopsies from Patients with Aspirin-intolerant Asthma. J Clin Invest. 1998;101(4):834-846.

Tanaka W, Tozzi CA, Reiss TF. Increase in urinary leukotriene LTE 4 levels in acute asthma: correlation with airflow limitation. 2004:100-104. doi:10.1136/thx.2004.006825.

Kanaoka Y, Maekawa A, Austen KF. Identification of GPR99 Protein as a Potential Third Cysteinyl Leukotriene Receptor with a Preference for Leukotriene E 4. J Biol Chem. 2013;288(16):10967-10972. doi:10.1074/jbc.C113.453704.

Bankova LG, Lai J, Yoshimoto E, Boyce JA, Austen KF, Kanaoka Y. Leukotriene E 4 elicits respiratory epithelial cell mucin release through the G-protein – coupled receptor , GPR99. Proc Natl Acad Sci U S A. 2016;113(22):6242-6247. doi:10.1073/pnas.1605957113.

Monneret G, Gravel S, Diamond M, Rokach J, Powell WS. Prostaglandin D 2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood. 2001;98(6):1942-1949.

Cahill KN, Bensko J, Boyce JA, Laidlaw TM. Prostaglandin D2 : A dominant mediator of aspirin exacerbated respiratory disease. J Allergy Clin Immunol. 2016;135(1):245-252. doi:10.1016/j.jaci.2014.07.031.Prostaglandin.

Liu T, Kanaoka Y, Barrett NA, et al. Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene − Driven IL-33 − Mediated Mast Cell Activation Pathway. J Immunol. 2015;195(8):3537-3545. doi:10.4049/jimmunol.1500905.

Buchheit KM, Cahill KN, Katz HR, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in aspirin-exacerbated respiratory diseas. J Allergy Clin Immunol. 2017;137(5):1566-1576. doi:10.1016/j.jaci.2015.10.020.Thymic.

Laidlaw TM, Kidder MS, Bhattacharyya N, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2011;119(16):1-3. doi:10.1182/blood-2011-10-384826.There.

Mitsui C, Kajiwara K, Hayashi H, Ito J, Mita H. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2017;137(2):400-411. doi:10.1016/j.jaci.2015.05.041.

Celik G, Schroeder J, Hamilton R, Saini S, Adkinson F. Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease. Clin Exp Allergy. 2010;39(10):1522-1531. doi:10.1111/j.1365-2222.2009.03277.x.Effect.

Lee RU, White AA, Ding D, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2010;105:130-135. doi:10.1016/j.anai.2010.05.020.

Berges-gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy, Asthma Immunol. 2002;89(5):474-478. doi:10.1016/S1081-1206(10)62084-4.

Graefe H, Roebke C, Sch D, Meyer JE. Aspirin Sensitivity and Chronic Rhinosinusitis with Polyps : A Fatal Combination. J Allergy (Cairo). 2012;2012(1). doi:10.1155/2012/817910.

Bousquet J, Bachert C, Canonica GW, Casale TB. Unmet needs in severe chronic upper airway disease ( SCUAD ). J Allergy Clin Immunol. 2017;124(3):428-433. doi:10.1016/j.jaci.2009.06.027.

Fahrenholz JM. Natural History and Clinical Features of Aspirin- Exacerbated Respiratory Disease. Clin Rev Allergy Immunol. 2003;24(2):113-124.

Kennedy JL, Stoner AN, Borish L. Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future. Am J Rhinol Allergy. 2016;30:407-413. doi:10.2500/ajra.2016.30.4370.

Schmidt JT, Bruïne FT De, Buchem MA Van, Sterk PJ, Rabe KF, Bel EH. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol. 2002;109(4):621-626. doi:10.1067/mai.2002.122458.

Woessner KM. Update on Aspirin-Exacerbated Respiratory Disease. Curr Allergy Asthma Rep. 2017;17(1):1-9. doi:10.1007/s11882-017-0673-6.

Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma , nasal polyps , and chronic sinusitis. Ann Allergy Asthma Immunol. 2008;100(5):420-425. doi:10.1016/S1081-1206(10)60465-6.

Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res. 2011. doi:10.4168/aair.2011.3.1.3.

Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, et al. EAACI/GA2LEN guideline: Aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy Eur J Allergy Clin Immunol. 2007;62(10):1111-1118. doi:10.1111/j.1398-9995.2007.01409.x.

Miller B, Mirakian R, Gane S, et al. Nasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated respiratory disease Experimental Allergy. Clin Exp Allergy. 2013;43:874-880. doi:10.1111/cea.12110.

White A, Bigby T, Stevenson D. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy, Asthma Immunol. 2006;97(2):190-195. doi:10.1016/S1081-1206(10)60012-9.

Herrera C, Cardona R, Gómez C, et al. Safety of meloxicam oral provocation challenge in patients with NSAID reaction. World Allergy Organ J. 2015;8(Suppl 1):A265. doi:10.1186/1939-4551-8-S1-A265.

Garret A, FitzGerald M, Patrono C. The Coxibs, Selective Inhibitors of Cyclooxygenasse-2. N Engl J Med. 2001;345(6):433-442.

Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96(13):7563-7568. doi:10.1073/pnas.96.13.7563.

Rao PNP, Knaus EE, Road TP, Jolla L. Evolution of Nonsteroidal Anti-Inflammatory Cyclooxygenase ( COX ) Inhibition and Beyond Drugs ( NSAIDs ): Cyclooxygenase (COX) Inhibition and Beyond. North. 2008;11(2):81-110.

Walgama ES, Hwang PH. Aspirin-Exacerbated Respiratory Disease. Otolaryngol Clin NA. 2017;50(1):83-94. doi:10.1016/j.otc.2016.08.007.

Parnes SM, Chuma A V. Acute effects of antileuko- trienes on sinonasal polyposis and sinusitis. Ear Nose Throat J. 2000;79(1):18-20, 24-25.

Wentzel JL, Soler ZM, Sc M, et al. Leukotriene antagonists in nasal polyposis : A meta-analysis and systematic review. Am J Rhinol Allergy. 2013;27(6):482-489. doi:10.2500/ajra.2013.27.3976.

Bergmann KC, Zuberbier T, Church MK. Omalizumab in the treatment of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(3):459-460. doi:10.1016/j.jaip.2015.01.012.

Porcaro F, Di Marco A, Cutrera R. Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria. Pediatr Pulmonol. 2017;52(5):E26-E28. doi:10.1002/ppul.23615.

Phillips-Angles E, Barranco P, Lluch-Bernal M, Dominguez-Ortega J, López-Carrasco V, Quirce S. Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab. J Allergy Clin Immunol Pract. 2016;5(3):842-845. doi:10.1016/j.jaip.2016.12.013.

Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110-116.e1. doi:10.1016/j.jaci.2012.07.047.

Zhang N, Holtappels G, Gevaert P, et al. Mucosal tissue polyclonal IgE is functional in response to allergen and SEB. Allergy. 2011;66(9):141-148. doi:10.1111/j.1398-9995.2010.02448.x.

Hayashi H, Mitsui C, Nakatani E, et al. Omalizumab reduces cysteinyl leukotriene and 9α11β prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(5):1585-1587e1. doi:10.1016/j.jaci.2015.09.034.

Cardona R, Diez LS, Giraldo RER, Sánchez JM. Desensibilización al ácido acetil-salicílico como tratamiento para la enfermedad respiratoria exacerbada por antiinflamatorios no esteroides. Iatreia. 2014;27(3):299-308.

Cardona R, Ramírez RH, Reina Z, Escobar MF, Morales E. Alergia e intolerancia a antiinflamatorios no esteroides: desensibilización exitosa en tres casos y revisión de la literatura. Biomédica. 2009;29:181-190.

Cho K, Soudry E, Psaltis AJ, et al. Long-term Sinonasal Outcomes of Aspirin Desensitization in Aspirin Exacerbated Respiratory Disease. Otolaryngol Head Neck Surg. 2014;151(4):2-8. doi:10.1177/0194599814545750.

Cortellini G, Caruso C, Romano A. Aspirin challenge and desensitization: how, when and why. Curr Opin Allergy Clin Immunol. 2017;17(4):247-254. doi:10.1097/ACI.0000000000000374.

Berges-gimeno MP, Simon RA, Stevenson DD, Jolla L. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111(1):180-186. doi:10.1067/mai.2003.7.

Waldram JD, Simon RA. Performing Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease. Immunol Allergy Clin North Am. 2016;36(4):693-703. doi:10.1016/j.iac.2016.06.006.

Steinke JW, Culp JA, Kropf E, Borish L. Modulation by aspirin of nuclear phospho – signal transducer and activator of transcription 6 expression : Possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol. 2009;124(4):724-730.e4. doi:10.1016/j.jaci.2009.07.031.

Chen JR, Buchmiller BL, Khan DA. An Hourly Dose-Escalation Desensitization Protocol for Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2015;3(6):926-931.e1. doi:10.1016/j.jaip.2015.06.013.




DOI: http://dx.doi.org/10.29262/ram.v0i0.315

Enlaces refback

  • No hay ningún enlace refback.


Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.